Safety and Performance of Ultra/Ultra 3D Cl With HiFocus SlimJ Electrode in Adults With Severe-to-profound Hearing Loss

Last updated: September 24, 2025
Sponsor: Advanced Bionics AG
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Hearing Impairment

Hearing Loss

Deafness

Treatment

cochlear implantation

Clinical Study ID

NCT04929470
ABIntl-19-45
  • Ages > 18
  • All Genders

Study Summary

This is a prospective study designed to evaluate the safety and performance of the HiResTM Ultra Cl HiFocusTM SlimJ Electrode and HiResTM Ultra 3D Cl HiFocusTM SlimJ Electrode (Ultra X) under normal conditions of use as it is approved for this device. Participants receive interventions as part of routine medical care.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • No previous experience with any auditory implant

  • 18 years of age or older

  • Postlingual onset of severe hearing loss (≥ 4 years of age)

  • Limited benefit from appropriately fitted hearing aids, defined as scoring 60% orless in Freiburger Monosyllabic word test

  • German language proficiency

  • Willingness to participate in all scheduled procedures outlined in the protocol

Exclusion

Exclusion Criteria:

  • Cochlear malformation or obstruction that would preclude full insertion of electrodearray.

  • Presence of additional disabilities that would prevent or interfere withparticipation in the required study procedures

  • Medical or psychological conditions that contraindicate surgery or impact theability to manage an implanted device or the study related procedures

  • Evidence of central auditory lesion or compromised auditory nerve

  • Pregnancy at time of surgery.

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: cochlear implantation
Phase:
Study Start date:
July 06, 2021
Estimated Completion Date:
May 31, 2026

Study Description

This study is set up to document any adverse events and comparing pre- to post-implant benefit to subjects. Any adverse events associated with the device will be documented via Advanced Bionics complaint handling system for the lifetime of the device. A within-subjects repeated-measures design will be employed. Speech perception will be evaluated preoperatively with conventional amplification to determine candidacy and to establish baseline performance. Efficacy parameters are speech perception data which will be collected according to clinical routine with a 6 month follow up period. Subjects will be implanted unilaterally with the Ultra X according to standard clinical care.

The primary efficacy objective is to demonstrate that mean monosyllabic word recognition score with the Ultra X used in combination with a sound processor programmed with the latest fitting software six months after activation is at least 20% better than the mean word score at baseline with conventional amplification in the same ear.

The primary efficacy endpoint is reached six months after device activation.

Connect with a study center

  • HNO-Klinik Düsseldorf

    Düsseldorf 2934246, Düsseldorf 40225
    Germany

    Site Not Available

  • Unfallkrankenhaus Berlin (UKB)

    Berlin 2950159, State of Berlin 2950157 12683
    Germany

    Site Not Available

  • Unfallkrankenhaus Berlin (UKB

    Berlin, 12683
    Germany

    Active - Recruiting

  • Unfallkrankenhaus Berlin (UKB)

    Berlin, 12683
    Germany

    Site Not Available

  • HNO-Klinik Düsseldorf

    Düsseldorf, 40225
    Germany

    Site Not Available

  • Westfälische Wilhelms-Universität Münster

    Münster,
    Germany

    Site Not Available

  • Westfälische Wilhelms-Universität Münster

    Münster 2867543,
    Germany

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.